Draft NICE guidance recommends use of Oncotype DX to guide early breast cancer treatment decisions

Source: NICE Area: News NICE has issued its third diagnostics consultation on gene expression profiling and expanded immunohistochemistry (protein expression profiling) tests to guide the use of adjuvant chemotherapy in early breast cancer management (MammaPrint, Oncotype DX, IHC4 and Mammostrat). These tests measure multiple markers within the tumour that may indicate how the tumour is likely to develop. This third consultation follows consultations on previous drafts and the submission of a confidential access proposal by the manufacturer of Oncotype DX.   The draft guidance recommends the use of Oncotype DX in people with oestrogen receptor positive (ER+), lymph node negative (LN-) and human epidermal growth factor receptor 2 negative (HER2-) early breast cancer to guide chemotherapy decisions if:   . The person is assessed as being at intermediate risk of distant recurrence, according to decision making tools/protocols currently in use in the NHS (e.g. the Nottingham ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news